Medicus Pharma’s Phase 2 study enrolls 25% of patients and expands into Asia-Pacific Region [Video]

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to to announce a new agreement with Swanielle to explore expanding the Phase 2 clinical study of a potential treatment for Basal Cell Carcinoma (BCC) into the Asia-Pacific region.

The ongoing Phase 2 study, currently being conducted at nine clinical sites in the United States, has already enrolled over 25% of the targeted 60 patients. Medicus Pharma plans to conduct an interim analysis of the data in Q1 2025 and submit the findings to the FDA for a Type C meeting in Q2 2025. This meeting will focus on aligning the clinical development pathway and potentially advancing the study into a pivotal phase to accelerate development.

Under the agreement, Swanielle, a healthcare consulting firm, will support Medicus in identifying pharmaceutical or biotech partners in Southeast Asia to facilitate the regional expansion of the study. This collaboration highlights Medicus Pharma’s dedication to developing innovative solutions for BCC and strengthening its global clinical development strategy.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma
#BasalCellCarcinoma #CancerTreatment #ClinicalTrials #NonInvasiveTherapy #Phase2Study #SkinCancer #AsiaPacificExpansion #MedicalInnovation #FDAFastTrack
#investing #investment #investor #stockmarket #stocks #stock #stockmarketnews